Epigenetic drugs show 375% increase in Series A venture financing in 2024
The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to $342m in 2024.
The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to $342m in 2024.
What's Your Reaction?
